Home » Stocks » CELC

Celcuity Inc. (CELC)

Stock Price: $20.68 USD -0.62 (-2.91%)
Updated Jul 26, 2021 4:00 PM EDT - Market closed
Market Cap 311.05M
Revenue (ttm) n/a
Net Income (ttm) -10.02M
Shares Out 14.90M
EPS (ttm) -0.96
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 26
Last Price $20.68
Previous Close $21.30
Change ($) -0.62
Change (%) -2.91%
Day's Open 21.30
Day's Range 20.34 - 21.40
Day's Volume 29,370
52-Week Range 5.00 - 33.01

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

MINNEAPOLIS, MN / ACCESSWIRE / July 8, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patien...

2 weeks ago - Accesswire

The clinical-stage biotech announced the pricing of a secondary stock offering.

3 weeks ago - The Motley Fool

MINNEAPOLIS, MN / ACCESSWIRE / June 28, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patie...

4 weeks ago - Accesswire

MINNEAPOLIS, MN / ACCESSWIRE / June 28, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patie...

4 weeks ago - Accesswire

MINNEAPOLIS, MN / ACCESSWIRE / June 9, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patien...

1 month ago - Accesswire

Entered into worldwide licensing agreement with Pfizer to develop and commercialize gedatolisib, a first-in-class PI3K/mTOR inhibitor, in clinical development for breast cancer Announced encouraging pre...

2 months ago - Accesswire

MINNEAPOLIS, MN / ACCESSWIRE / April 26, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic (CDx) and therapeutic strategy for treatin...

3 months ago - Accesswire

Celcuity, Inc. (CELC) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through...

3 months ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in Celcuity Inc. (CELC).

3 months ago - Zacks Investment Research

- Inhibition of hyperactive RAS network signaling is nine times more effective with gedatolisib than with a PI3K-α inhibitor - - Synergistic cooperation between PI3K/mTOR and BCL signaling detected, sug...

3 months ago - Accesswire

180 Life Sciences Corp (NASDAQ: ATNF) shares are trading higher following insider buying from Marc Feldmann, a director on the company's board, and Jonathan Rothbard, the company's chief scientific offi...

Other stocks mentioned: ATNF
3 months ago - Benzinga

Celcuity broke out and soared to a nearly two-year high Friday after striking a licensing deal with Pfizer for a breast cancer treatment. Celcuity paid Pfizer $10 million in cash and stock.

3 months ago - Investors Business Daily

Celcuity Inc (NASDAQ: CELC) shares are trading higher after the company announced a worldwide licensing agreement with Pfizer Inc. (NYSE: PFE) to develop and commercialize gedatolisib. Celcuity is a cel...

Other stocks mentioned: PRVB
3 months ago - Benzinga

Celcuity Inc (NASDAQ: CELC) has entered into a global licensing agreement with Pfizer Inc (NYSE: PFE), granting Celcuity exclusive rights to Pfizer's gedatolisib. The pan-PI3K/mTOR inhibitor is currentl...

3 months ago - Benzinga

MINNEAPOLIS--(BUSINESS WIRE)--Celcuity reports preliminary data for gedatolosib and provides corporate update

3 months ago - Business Wire

MINNEAPOLIS--(BUSINESS WIRE)-- #cancer--Celcuity has entered a global licensing agreement with Pfizer granting exclusive rights to Pfizer's cancer drug gedatolisib for breast cancer.

3 months ago - Business Wire

Celcuity Inc (NASDAQ: CELC) has announced a clinical trial collaboration with the MD Anderson Cancer Center, Novartis AG (NYSE: NVS), and Puma Biotechnology Inc (NASDAQ: PUMA) to conduct a Phase 2 clini...

Other stocks mentioned: NVS, PBYI
4 months ago - Benzinga

MINNEAPOLIS, MN / ACCESSWIRE / March 1, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical stage biotechnology company translating discoveries of new cancer sub-types into 3rd generation diagnostics and exp...

4 months ago - Accesswire

Celcuity Inc (NASDAQ: CELC) has priced its upsized underwritten public offering of 1.7 million shares at $14 per share, raising approximately $24 million in gross proceeds. The offer price is at an 11% ...

5 months ago - Benzinga

- UCLA Jonsson Comprehensive Cancer Center and Vanderbilt-Ingram Cancer Center will also participate - Study will evaluate the efficacy and safety of NERLYNX® and FASLODEX® in metastatic HR-positive, HE...

7 months ago - Accesswire

Celcuity Inc. (CELC) CEO Brian Sullivan on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Celcuity Inc. (CELC) CEO Brian Sullivan on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Celcuity Inc. (CELC) CEO Brian Sullivan on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

While domestic economic growth has been benefiting small-cap stocks until now, you should consider selling some of the stocks before entering 2020 because of poor earnings growth projections.

Other stocks mentioned: AAWW, BPFH, RRGB
1 year ago - Zacks Investment Research

Celcuity Inc. (CELC) CEO Brian Sullivan on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Celcuity, Inc. (CELC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 year ago - Zacks Investment Research

Celcuity, Inc. (CELC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.

1 year ago - Zacks Investment Research

Celcuity's (CELC) CEO Brian Sullivan on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Celcuity, Inc. (CELC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.

2 years ago - Zacks Investment Research

Celcuity, Inc. (CELC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

2 years ago - Zacks Investment Research

About CELC

Celcuity Inc., a clinical stage biotechnology company, discovers cancer sub-types and therapeutic options for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. Celcuity Inc. was found... [Read more...]

Industry
Diagnostics & Research
IPO Date
Sep 20, 2017
Stock Exchange
NASDAQ
Ticker Symbol
CELC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for Celcuity stock is "Buy." The 12-month stock price forecast is 30.00, which is an increase of 45.07% from the latest price.

Price Target
$30.00
(45.07% upside)
Analyst Consensus: Buy